Concepedia

Author

Sandra Philipp

Charité - Universitätsmedizin BerlinORCID

Also Known As

A. Becker, A. Peserico, Philipp S., Philipp, Sandra, S Philipp, S. Philipp, Sandra PHILIPP, Sandra Philipp, Sandra Philipp MD, PhD, Spitzer Philipp

179

Publications

6.3K

Citations

41

H-Index

57

Concepts

All Affiliations

Charité - Universitätsmedizin BerlinUniversity of LübeckUniversität HamburgUniversity Medical Center Hamburg-EppendorfUniversity Hospital Schleswig-Holstein
SP

About

Sandra Philipp is an author at Charité - Universitätsmedizin Berlin specializing in medicine, dermatology, and psoriatic arthritis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

18

19

1.8K

2

Engineering

1

1

18

3

Health Sciences

1

1

37

4

Biomedical Engineering

1

1

18

5

Cell Biology

1

1

30

Sandra Philipp

×

53

Publications

4.8K

Citations

37

H-Index

YearCitations

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Kim Papp, Andrew Blauvelt, Michael Bukhalo,

New England Journal of Medicine

2017

504

IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not

Kerstin Wolk, Harald S. Haugen, Wenfeng Xu,

Journal of Molecular Medicine

2009

403

S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

Alexander Nast, Wolf‐­Henning Boehncke, Ulrich Mrowietz,

JDDG Journal der Deutschen Dermatologischen Gesellschaft

2012

271

Increased Prevalence of Metabolic Syndrome in Patients with Acne Inversa

Robert Sabat, Akewit Chanwangpong, Sylke Schneider‐Burrus,

PLoS ONE

2012

249

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

Ian Landells, Colleen Marano, Ming-Chun Hsu,

Journal of the American Academy of Dermatology

2015

220

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

Andrew Blauvelt, Craig L. Leonardi, Melinda Gooderham,

JAMA Dermatology

2020

201

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Atul Deodhar, Alice B. Gottlieb, Wolf‐­Henning Boehncke,

The Lancet

2018

181

The Th17 cytokine IL‐22 induces IL‐20 production in keratinocytes: A novel immunological cascade with potential relevance in psoriasis

Kerstin Wolk, Ellen Witte, Katarzyna Warszawska,

European Journal of Immunology

2009

175

IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis

Ellen Witte, Georgios Kokolakis, Katrin Witte,

Journal of Investigative Dermatology

2014

158

Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial

Kim Papp, Diamant Thaçi, Danielle Marcoux,

The Lancet

2017

147

Page 1